on ABIVAX (EPA:ABVX)
Abivax welcomes Dr. Dominik Höchli to its Board of Directors
On April 22, 2025, Abivax announced the appointment of Dr. Dominik Höchli to its Board of Directors. Specializing in immunology, the company is preparing to publish data from its Phase 3 study in ulcerative colitis in the third quarter of 2025.
Dr. Höchli, with over twenty years of experience, notably at AbbVie, brings valuable strategic expertise to Abivax. His experience spans medical affairs and product positioning, both essential for the company's clinical trials.
Sylvie Grégoire, Chair of the Board, welcomes this appointment, highlighting the strategic importance of this expertise for the development of obefazimod.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news